OR Oncology Reports 1021-335X 1791-2431 D.A. Spandidos 10.3892/or.2017.5376 or-37-03-1593 Articles MicroRNA-194 represses glioma cell epithelial-to-mesenchymal transition by targeting Bmi1 ZhangXi 1 * WeiChunyan 2 * LiJin 1 LiuJiali 3 QuJianqiang 1 Department of Neurosurgery, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China Department of Gynaecology and Obstetrics, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China Department of Clinical Laboratory, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China Correspondence to: Dr Jianqiang Qu, Department of Neurosurgery, The Second Affiliated Hospital of Xi'an Jiaotong University, No. 157 West 5th Road, Xi'an, Shaanxi 710004, P.R. China, E-mail: qujianqiangxa@163.com

Contributed equally

 032017 17012017 37 3 1593 1600 16082016 03012017 Copyright © 2017, Spandidos Publications 2017

MicroRNA-194 (miR-194) is frequently dysregulated in many types of cancer. However, the function of miR-194 in glioma remains unknown. In the present study, we aimed to investigate the biological functions of miR-194 in glioma and the potential molecular mechanism of miR-194 involved in glioma progression. We found that miR-194 expression was significantly reduced in glioma specimens and cell lines, as detected by real-time quantitative polymerase chain reaction (RT-qPCR) analysis. The overexpression of miR-194 inhibited while the suppression of miR-194 promoted cell migration, invasion and epithelial mesenchymal transition (EMT) in glioma cells. Bioinformatics analysis showed that the B cell-specific moloney murine leukemia virus insertion site 1 (Bmi1) was a direct target of miR-194, which was validated by Dual-Luciferase reporter assay, RT-qPCR and western blot analysis. The restoration of Bmi1 expression significantly abrogated the suppressive effect of miR-194 on glioma cell EMT. Taken together, the present study suggests that miR-194 inhibits glioma cell EMT by targeting Bmi1 providing novel insights into understanding the pathogenesis of glioma. The restoration of miR-194 may be a potential therapeutic strategy for glioma treatment.

 glioma miR-194 Bmi1 epithelial-to-mesenchymal transition Introduction

Glioma is one of the most prevalent brain tumors, with a high yearly mortality rate worldwide (1,2). In spite of the current advances in cancer treatments, glioma is still an intractable disease due to the rapid growth, angiogenesis and metastasis of glioma cells (3,4). The overall survival has not been significantly improved during the past decades (4,5). Therefore, there is an urgent need to develop new therapies for glioma. However, the mechanism of glioma tumorigenesis is still not fully understood that hampers the development of new treatments for glioma.

In recent years, microRNAs (miRNAs), a group of small and non-coding RNA, have emerged as potential and promising tools for cancer diagnosis and treatments (6,7). miRNAs can regulate target gene expression by interacting with the 3-untranslated region (UTR) of the mRNA that inhibits translation or induces mRNA degradation (8,9). Thus, miRNAs function as native regulators of gene expression. miRNAs are capable of modulating cancer cell proliferation, apoptosis, differentiation, migration and invasion by targeting oncogenes or tumor suppressors (10). There is increasing evidence suggesting that various miRNAs are dysregulated in glioma, which function as oncogenes or tumor suppressors (11,12), highlighting their potential as novel agents for the treatment of glioma. However, the precise role of miRNAs in glioma remains largely unknown.

The B cell-specific moloney murine leukemia virus insertion site 1 (Bmi1) is a self-renewal gene that is overexpressed in multiple human cancers (13). Bmi1 is a key component of the polycomb regulatory complex-1 regulating the transcription of a variety of important genes (14,15). The inhibition of Bmi1 induces tumor cell apoptosis and increases susceptibility to chemotherapy and radiation therapy, indicating an oncogenic role of Bmi1 (16,17). Bmi1 can induce cell transformation and promote cancer proliferation in vivo and in vitro through transcriptional repression of tumor suppressor genes including p16INK4A and p14ARF (18–20). The epithelial-to-mesenchymal transition (EMT) is an essential process for cancer invasion and metastasis (21). Notably, a recent study has shown that Bmi1 plays an important role in inducing EMT (22–24). Bmi1 plays an important role in glioma tumorigenesis through promoting the invasion, migration, angiogenesis and proliferation of glioma cells (25–28). Therefore, targeted therapy on Bmi1 may have promising and potential therapeutic values on glioma treatment.

Emerging evidence has suggested that miR-194 functions as a tumor suppressor in many types of human cancers including lung cancer (29), hepatocellular carcinoma (30) and colorectal cancer (31). However, the role of miR-194 in glioma remains unclear. In the present study, we aimed to explore the biological role of miR-194 and the underlying molecular mechanism in regulating glioma procession. We found that miR-194 expression was significantly decreased in glioma tissues and cell lines. Overexpression of miR-194 inhibited while the suppression of miR-194 promoted cell migration, invasion and EMT of glioma cells. Bioinformatic analysis indicated that Bmi1 was the direct target of miR-194 in glioma cells by which miR-194 regulated the glioma EMT process. Our findings provide a better understanding of the mechanism of glioma development and suggest that targeting Bmi1 by miR-194 may serve as an attractive treatment method for glioma.

 Materials and methods <sec> <title>Tissue specimens and cell line

A total of 20 glioma specimens were histopathologically diagnosed at the Department of Neurosurgery, the Second Affiliated Hospital of Xi'an Jiaotong University (Xi'an, China). The specimens were resected prior to any therapeutic treatment. Normal brain tissues obtained from internal decompression patients undergoing surgical operation were used as a control. Prior written informed consent of the patients and approval were obtained from the Institutional Human Experiment and Ethic Committee of the Second Affiliated Hospital of Xi'an Jiaotong University. This study was performed in accordance with the Helsinki Declaration. U87, U251, SHG44 and A172 glioma cell lines and normal human astrocytes (NHA) were purchased from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). All cells were routinely cultured in Dulbeccos modified Eagles medium (DMEM; Gibco, Rockville, MD, USA) containing 10% fetal bovine serum (FBS; Gibco) and 1% penicillin/streptomycin mix (Sigma-Aldrich, St. Louis, MO, USA) in a humidified atmosphere containing 5% CO2 at 37°C.

 Real-time quantitative polymerase chain reaction (RT-qPCR)

Total RNA was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) as per the manufacturers instructions. For the analysis of Bmi1 expression, RNA was reverse-transcribed into cDNA by Moloney murine leukemia virus (M-MLV) reverse transcriptase (Takara Bio, Dalian, China). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal control for normalization. For the analysis of miR-194 expression, RNA was reverse-transcribed into cDNA by TaqMan MicroRNA reverse transcription kit (Applied Biosystems, Inc., Carlsbad, CA, USA). Small nuclear RNA U6 was used for normalization. The PCR amplification was performed by using the SYBR-Green Master Mix kit (Bio-Rad Laboratories, Hercules, CA, USA) on an Applied Biosystems AB 7500 real-time PCR system (Applied Biosystems). The primers used were as follows: miR-194, forward, 5-atggacctggggccacgaag-3 and reverse, 5-tctggcct gggagcgtcg-3; U6, forward, 5-cgcttcggcagcacatatactaa-3 and reverse, 5-tatggaacgcttcacgaatttgc-3; Bmi1, forward, 5-atgca tcgaacaacgagaatcaagatcact-3 and reverse, 5-tcaaccagaagaa gttgctgatgaccc-3; and GAPDH, forward, 5-ccatgttcgtcatggtg tg-3 and reverse, 5-ggtgctaagcagttggtggtg-3. Gene expression was calculated using the 2−ΔΔCt method, normalized against U6 or GAPDH and then compared with the control group.

 Oligonucleotides, plasmids and transfection

miR-194 mimics, miR-194 inhibitor and their negative controls were purchased from Shanghai GenePharma, Co., Ltd. (Shanghai, China). The open reading frame of Bmi1 was inserted into the pcDNA3.0 vector (Invitrogen). All the transfections were performed using Lipofectamine 2000 (Invitrogen) according to the manufacturers instructions.

 Migration and invasion assay

For cell migration, 1×105 cells transfected with miR-194 mimics or miR-194 inhibitors were placed in the upper chambers of a Transwell (Costar, Cambridge, MA, USA) with serum-free medium and the lower chambers were filled with medium containing 10% FBS. For cell invasion, the upper chambers were coated with Matrigel (BD Biosciences, San Jose, CA, USA). After being cultured for 24 h at 37°C, the non-migrated or non-invaded cells on the top of the well were gently removed and the cells on the lower surface of the membrane were fixed with 70% ethanol and stained with 0.1% violet (Sigma-Aldrich). The cells were observed and counted under a microscope (Olympus Corp., Tokyo, Japan).

 Western blot analysis

Proteins were extracted by cell lysis buffer and the protein concentration was detected by a BCA kit (Beyotime Institute of Biotechnology, Haimen, China). A total of 50 µg protein was separated by SDS-PAGE and electrotransferred to a polyvinylidene fluoride membrane (Bio-Rad Laboratories). The membrane was blocked by 5% non-fat milk and then incubated with primary antibodies at 4°C overnight. The membrane was then incubated with horseradish peroxidase-conjugated secondary antibodies (Bosis, Beijing, China) for 1 h at 37°C. Ultimately, the membrane was detected by an ECL western blotting kit (Pierce, Rockford, IL, USA) according to the manufacturers instructions. The image was analyzed by Image-Pro Plus 6.0 software (Media Cybernetics, Inc., Rockville, MD, USA). The values were normalized against GAPDH and then were compared with the control group. Primary antibodies used in this experiment including anti-E-cadherin, anti-vimentin, anti-Bmi1 and anti-GAPDH were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

 Dual-Luciferase reporter assay

The Bmi1 3-UTR harboring the seed-matched sequences of miR-194 with or without mutation was inserted into pmirGLO Dual-Luciferase vector (Promega Corp., Madison, WI, USA). Glioma cells were seeded into 24-well plates and co-transfected with miR-194 mimics or miR-194 inhibitor and the constructed wild-type or mutant pmirGLO-Bmi1 3-UTR into glioma cells using Lipofectamine 2000. After 48 h, the luciferase activity was analyzed by a Dual-luciferase reporter assay system kit (Promega).

 Data analysis

Data are reported as means ± standard deviation (SD). Statistical analyses were performed using SPSS version 11.5 software (SPSS, Inc., Chicago, IL, USA). Differences were calculated by the Students t-test or one-way analysis of variance (ANOVA) followed by Bonferroni post hoc. When the P-value was <0.05, the difference was considered to be statistically significant.

 Results <sec> <title>miR-194 is frequently lower in glioma tissues and cell lines

To determine whether miR-194 is involved in glioma development, we first analyzed the expression patterns of miR-194 in glioma specimens by RT-qPCR. The results showed that miR-194 was frequently downregulated in glioma tissues compared with normal brain tissue (Fig. 1A). Moreover, the expression levels of miR-194 were also decreased in the four glioma cell lines examined, particularly in A172 and U87, when compared with normal human astrocytes (Fig. 1B). These results indicate that miR-194 may play an important role in glioma.

 miR-194 suppresses glioma cell migration and invasion

To investigate the biological role of miR-194 in glioma, we performed gain- and loss-of-function experiments by transiently transfecting miR-194 mimics or miR-194 inhibitors in A172 and U87 cells. We then detected the functional effect of miR-194 on glioma cell migration and invasion by Transwell assay. The results showed that miR-194 overexpression significantly inhibited glioma cell migration (Fig. 2A and C) and invasion (Fig. 2B and D) in A172 and U87 cells. Conversely, miR-194 suppression markedly increased glioma cell migration (Fig. 2A and C) and invasion (Fig. 2B and D). These data imply a suppressive role of miR-194 on glioma metastasis.

 miR-194 suppresses EMT of glioma cells

To further investigate the contribution of miR-194 on glioma metastasis, we examined the biological role of miR-194 in regulating glioma cell EMT. Western blot analysis showed that the expression of epithelial marker E-cadherin was significantly increased, whereas expression of the mesenchymal marker vimentin was markedly decreased by miR-194 overexpression in A172 cells (Fig. 3A-C). In contrast, miR-194 suppression showed the opposite effects (Fig. 3A-C). Similar results were also observed in U87 cells (Fig. 3D-F), suggesting a suppressive role of miR-194 in glioma cell EMT.

 miR-194 directly targets Bmi1

To investigate the underlying molecular mechanism by which miR-194 regulates glioma cell EMT, we used bioinformatic analysis to identify the potential target of miR-194. Among these predicted target genes, Bmi1, an important regulator for cancer metastasis (22–24), caught our attention. The predicted binding site between miR-194 and Bmi1 3-UTR is illustrated in Fig. 4A. To verify that Bim1 is a direct target gene of miR-194, we performed a Dual-Luciferase reporter assay. The 3-UTR fragments of Bmi1, which contain a wild-type or mutant binding site of miR-194, were cloned into the luciferase reporter vector. Overexpression of miR-194 significantly restrained the luciferase activity in U87 cells transfected with luciferase reporter vector containing wild-type Bmi1 3-UTR, whereas miR-194 suppression promoted the luciferase activity (Fig. 4B). However, neither miR-194 overexpression nor suppression showed an obvious effect on luciferase activity of the luciferase reporter vector containing a mutant 3-UTR (Fig. 4C). Next, we further determined the direct effect of miR-194 on regulating Bmi1 expression. RT-qPCR analysis showed that the mRNA expression of Bmi1 was significantly decreased or increased by miR-194 overexpression or suppression, respectively (Fig. 5A and B). Consistently, western blot analysis identified that Bmi1 protein expression was regulated by miR-194 (Fig. 5C and D). Taken together, these results suggest that miR-194 regulates Bmi1 expression by directly targeting the 3-UTR of Bmi1.

 miR-194 inhibits glioma EMT through downregulating Bmi1

To verify whether the tumor suppressor role of miR-194 in glioma is mediated by suppressing the expression of Bmi1, we performed a rescue assay. Glioma cells were co-transfected with miR-194 mimics and Bmi1-overexpressing vector. The decreased protein expression of Bmi1 induced by miR-194 overexpression was significantly restored by transfection with a Bmi1-overexpressing vector (Fig. 6A and E). As expected, the inhibitory role of miR-194 on glioma EMT was rescued by Bmi1 overexpression (Fig. 6A-H). These results suggest that the suppressive role of miR-194 on glioma EMT is mediated by inhibiting Bmi1.

 Discussion

It has now been clearly established that miRNAs play an important role in regulating the tumorigenesis and metastasis of glioma (32–34). Therefore, the identification of glioma-associated miRNAs as biomarkers for glioma diagnosis, prognosis and treatment is of great importance. In the present study, we found that miR-194 was a novel glioma-associated miRNA that was decreased in glioma specimens and cell lines. The functional experiments indicated that miR-194 inhibited glioma cell migration, invasion and EMT, possibly through targeting and regulating Bmi1. Collectively, our data suggest that miR-194 plays an important role in glioma procession, indicating a novel therapeutic target for glioma.

Growing evidence has demonstrated that miR-194 is a tumor-associated miRNA that is frequently dysregulated in many types of human cancers. miR-194 expression was markedly decreased in hepatocellular carcinoma and miR-194 overexpression inhibited cell proliferation by targeting mitogen-activated protein kinase 4 (30). Other studies reported that miR-194 was frequently downregulated in colorectal cancer (35,36). miR-194 can inhibit colorectal carcinogenesis by targeting mitogen-activated protein kinase 4 (37) or Akt2 (31). Several studies have reported that miR-194 represses the progression and metastasis of non-small lung cancer through targeting bone morphogenetic protein 1 and p27kip1 (38), forkhead box A1 protein (39) and human nuclear distribution protein C (29). miR-194 can suppress gastric cancer cell proliferation and EMT through targeting RING box protein 1 (40) and forkhead box protein M1 (41). The tumor suppressive role of miR-194 is also observed in oral squamous cell carcinoma (42), bladder cancer (43) and clear cell renal cell carcinoma (44). However, the role of miR-194 in glioma remains unknown. In line with these findings, this study demonstrated that miR-194 functioned as a tumor suppressor in glioma. We found that miR-194 was decreased in glioma tissues and cell lines. Overexpression of miR-194 inhibited glioma cell migration, invasion and EMT through inhibiting Bmi1. However, an oncogenic role of miR-194 is observed in pancreatic ductal adenocarcinoma that promotes tumor growth and progression through inhibiting the tumor suppressor DACH1 (45). Therefore, the precise role of miR-194 in cancer progression requires further investigation.

Bmi1 has been suggested as an oncogene that is frequently elevated in various cancer types and is correlated with a worse prognosis (13). Bmi1 has been reported to inhibit tumor suppressor genes including p14ARF, p16INK4a, KIF1Bβ and TSLC1 (46). Bmi1 is a critical regulator for EMT and cancer metastasis (47). Knockdown of Bmi1 abolishes the ionizing irradiation-induced EMT of breast cancer cells (48). Twist1 and Bmi-1 can act cooperatively to inhibit E-cadherin and p16INK4a, leading to EMT induction (49). Bmi1 plays an important role in development of the central nervous system; however, the dysregulation of Bmi1 contributes to the development of brain tumors (50,51). Overexpression of Bmi1 was found in human medulloblastomas, correlated with activation of the sonic hedgehog pathway (50). Bmi1 is highly elevated in glioma tissues and patients with high levels of Bmi1 show a poor survival rate (52). Bmi1 promotes glioma cell migration and invasion via nuclear factor kappa B and p16 (25,28,53). Consistently, our results showed that the inhibition of Bmi1 by miR-194 significantly suppressed the glioma cell migration, invasion and EMT, further implying that Bmi1 can serve as a therapeutic target for preventing glioma metastasis.

In the present study, we demonstrated that miR-194 functions as an EMT regulator in glioma via targeting Bmi1. We showed that miR-194 could directly target the 3-UTR of Bmi1 and inhibit Bmi1 expression. Our findings are consistent with a previous study which revealed that miR-194 suppresses the EMT of endometrial cancer cells by targeting Bmi1 (54). The present study further confirms that Bmi1 is a functional target of miR-194. A recent study (55) suggested that targeting Bmi1 by miRNAs is a promising strategy for cancer prevention. Deng et al (55) reported that miR-376c suppresses cervical cancer cell proliferation and invasion by targeting Bmi1. miR-494-3p enhances the radiosensitivity of oral squamous carcinoma cells through targeting Bmi1 (56). miR-452 and miR-403 can inhibit the metastasis of non-small cell lung cancer through inhibiting Bmi1 (57,58). miR-218, functioning as a negative regulator of Bmi1, is also found in bladder cancer (59) and esophageal squamous cell carcinoma (60). Besides these miRNAs, miR-429, miR-200c, mIR-221 and miR-320a have been demonstrated to directly target Bmi1 in various cancer cells (22,61–63). These studies indicate that Bim1 undergoes epigenetic regulation by various miRNAs that may contribute to the development of cancer. A better understanding of Bmi1 by miRNAs will provide a new insight into understanding glioma pathogenesis.

EMT is considered as major modulator of metastasis formation in epithelial solid tumors, and the EMT of glioma has also been widely studied (64). Twist1, ZEB1/ZEB2 and SNAI1/SNAI2 have been suggested as the major regulators for EMT in glioma (65–67). Various miRNAs such as miR-200b, miR-590-3p and miR-181c are reported to be involved in regulating EMT of glioma (68–70). Our present study showed for the first time that miR-194 was decreased in glioma which could inhibit glioma cell migration, invasion and EMT. Importantly, we found that Bmi1 was a direct target of miR-194 in glioma cells by which miR-194 inhibited glioma cell EMT. miR-194 may serve as a novel biomarker as well as a therapeutic target in glioma. However, further in vivo studies are required to fully elucidate the exact role and molecular mechanism of miR-194 in the regulation of glioma.

 Acknowledgements

The present study was supported by the Social Research and Development Program of Shaanxi Province (no. 2016SF-110).

 Abbreviations Bmi1

B cell-specific moloney murine leukemia virus insertion site

 EMT

epithelial-to-mesenchymal transition

 FBS

fetal bovine serum

 miRNAs

microRNAs

 RT-qPCR

real- time quantitative polymerase chain reaction

 UTR

3-untranslated region

 References WestphalMLamszusKThe neurobiology of gliomas: From cell biology to the development of therapeutic approachesNat Rev Neurosci12495508201110.1038/nrn306021811295 SiegelRLMillerKDJemalACancer statistics, 2016CA Cancer J Clin66730201610.3322/caac.2133226742998 FurnariFBFentonTBachooRMMukasaAStommelJMSteghAHahnWCLigonKLLouisDNBrennanCMalignant astrocytic glioma: Genetics, biology, and paths to treatmentGenes Dev2126832710200710.1101/gad.159670717974913 PollackIFNeuro-oncology: Therapeutic benefits of reirradiation for recurrent brain tumorsNat Rev Neurol6533535201010.1038/nrneurol.2010.14420927054 KhasrawMLassmanABNeuro-oncology: Late neurocognitive decline after radiotherapy for low-grade gliomaNat Rev Neurol5646647200910.1038/nrneurol.2009.19419953115 PangJCKwokWKChenZNgHKOncogenic role of microRNAs in brain tumorsActa Neuropathol117599611200910.1007/s00401-009-0525-019343354 SilberJJamesCDHodgsonJGmicroRNAs in gliomas: Small regulators of a big problemNeuromolecular Med11208222200910.1007/s12017-009-8087-919731102 BartelDPMicroRNAs: Genomics, biogenesis, mechanism, and functionCell116281297200410.1016/S0092-8674(04)00045-514744438 WinterJJungSKellerSGregoryRIDiederichsSMany roads to maturity: microRNA biogenesis pathways and their regulationNat Cell Biol11228234200910.1038/ncb0309-22819255566 ManikandanJAarthiJJKumarSDPushparajPNOncomirs: The potential role of non-coding microRNAs in understanding cancerBioinformation2330334200810.6026/97320630002330186857192478731 ZhangYDuttaAAbounaderRThe role of microRNAs in glioma initiation and progressionFront Biosci (Landmark Ed)17700712201210.2741/3952222017693278211 BesseASanaJFadrusPSlabyOMicroRNAs involved in chemo- and radioresistance of high-grade gliomasTumour Biol3419691978201310.1007/s13277-013-0772-523568705 CaoLBombardJCintronKSheedyJWeetallMLDavisTWBMI1 as a novel target for drug discovery in cancerJ Cell Biochem11227292741201110.1002/jcb.2323421678481 GuneyIWuSSedivyJMReduced c-Myc signaling triggers telomere-independent senescence by regulating Bmi-1 and p16INK4aProc Natl Acad Sci USA10336453650200610.1073/pnas.0600069103165374491450136 SilvaJGarcíaJMPeñaCGarcíaVDomínguezGSuárezDCamachoFIEspinosaRProvencioMEspañaPImplication of polycomb members Bmi-1, Mel-18, and Hpc-2 in the regulation of p16INK4a, p14ARF, h-TERT, and c-Myc expression in primary breast carcinomasClin Cancer Res1269296936200610.1158/1078-0432.CCR-06-078817145810 WuJHuDYangGZhouJYangCGaoYZhuZDown-regulation of BMI-1 cooperates with artemisinin on growth inhibition of nasopharyngeal carcinoma cellsJ Cell Biochem11219381948201110.1002/jcb.2311421445878 WuZMinLChenDHaoDDuanYQiuGWangYOverexpression of BMI-1 promotes cell growth and resistance to cisplatin treatment in osteosarcomaPLoS One6e14648201110.1371/journal.pone.0014648213115993032734 JacobsJJScheijenBVonckenJWKieboomKBernsAvan LohuizenMBmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARFGenes Dev1326782690199910.1101/gad.13.20.267810541554317101 JiangLLiJSongLBmi-1, stem cells and cancerActa Biochim Biophys Sin (Shanghai)41527534200910.1093/abbs/gmp04019578716 ItahanaKZouYItahanaYMartinezJLBeausejourCJacobsJJVan LohuizenMBandVCampisiJDimriGPControl of the replicative life span of human fibroblasts by p16 and the polycomb protein Bmi-1Mol Cell Biol23389401200310.1128/MCB.23.1.389-401.200312482990140680 KalluriRWeinbergRAThe basics of epithelial-mesenchymal transitionJ Clin Invest11914201428200910.1172/JCI39104194878182689101 QiuMLiangZChenLTanGWangKLiuLLiuJChenHMicroRNA-429 suppresses cell proliferation, epithelial-mesenchymal transition, and metastasis by direct targeting of BMI1 and E2F3 in renal cell carcinomaUrol Oncol33332.e918201510.1016/j.urolonc.2015.03.016 WeiXLDouXWBaiJWLuoXRQiuSQXiDDHuangWHDuCWManKZhangGJERα inhibits epithelial-mesenchymal transition by suppressing Bmi1 in breast cancerOncotarget62170421717201510.18632/oncotarget.3966260237344673297 ParanjapeANBalajiSAMandalTKrushikEVNagarajPMukherjeeGRangarajanABmi1 regulates self-renewal and epithelial to mesenchymal transition in breast cancer cells through NanogBMC Cancer14785201410.1186/1471-2407-14-785253488054223733 LiangJWangPXieSWangWZhouXHuJShiQZhangXYuRBmi-1 regulates the migration and invasion of glioma cells through p16Cell Biol Int39283290201510.1002/cbin.1039025262972 TuYGaoXLiGFuHCuiDLiuHJinWZhangYMicroRNA-218 inhibits glioma invasion, migration, proliferation, and cancer stem-like cell self-renewal by targeting the polycomb group gene Bmi1Cancer Res7360466055201310.1158/0008-5472.CAN-13-035823950210 JiangLSongLWuJYangYZhuXHuBChengSYLiMBmi-1 promotes glioma angiogenesis by activating NF-κB signalingPLoS One8e55527201310.1371/journal.pone.0055527233832163561301 JiangLWuJYangYLiuLSongLLiJLiMBmi-1 promotes the aggressiveness of glioma via activating the NF-kappaB/MMP-9 signaling pathwayBMC Cancer12406201210.1186/1471-2407-12-406229670493502583 ZhouLDiQSunBWangXLiMShiJMicroRNA-194 restrains the cell progression of non-small cell lung cancer by targeting human nuclear distribution protein COncol Rep3534353444201627035759 ZhaoYLiFZhangXLiuAQiJCuiHZhaoPMicroRNA-194 acts as a prognostic marker and inhibits proliferation in hepatocellular carcinoma by targeting MAP4K4Int J Clin Exp Pathol812446124542015267224314680376 ZhaoHJRenLLWangZHSunTTYuYNWangYCYanTTZouWHeJZhangYMiR-194 deregulation contributes to colorectal carcinogenesis via targeting AKT2 pathwayTheranostics411931208201410.7150/thno.8712252851684183997 KwakPBIwasakiSTomariYThe microRNA pathway and cancerCancer Sci10123092315201010.1111/j.1349-7006.2010.01683.x20726859 KarsyMArslanEMoyFCurrent progress on understanding MicroRNAs in glioblastoma multiformeGenes Cancer3315201210.1177/1947601912448068228937863415667 TivnanAMcDonaldKLCurrent progress for the use of miRNAs in glioblastoma treatmentMol Neurobiol48757768201310.1007/s12035-013-8464-023625340 ChiangYSongYWangZLiuZGaoPLiangJZhuJXingCXuHmicroRNA-192, −194 and −215 are frequently downregulated in colorectal cancerExp Ther Med3560566201222969930 BasatiGRazaviAEPakzadIMalayeriFACirculating levels of the miRNAs, miR-194, and miR-29b, as clinically useful biomarkers for colorectal cancerTumour Biol3717811788201610.1007/s13277-015-3967-026318304 WangBShenZLGaoZDZhaoGWangCYYangYZhangJZYanYCShenCJiangKWMiR-194, commonly repressed in colorectal cancer, suppresses tumor growth by regulating the MAP4K4/c-Jun/MDM2 signaling pathwayCell Cycle1410461058201510.1080/15384101.2015.1007767256023664615039 WuXLiuTFangOLeachLJHuXLuoZmiR-194 suppresses metastasis of non-small cell lung cancer through regulating expression of BMP1 and p27kip1Oncogene3315061514201410.1038/onc.2013.10823584484 ZhuXLiDYuFJiaCXieJMaYFanSCaiHLuoQLvZmiR-194 inhibits the proliferation, invasion, migration, and enhances the chemosensitivity of non-small cell lung cancer cells by targeting forkhead box A1 proteinOncotarget713139131522016269096124914347 ChenXWangYZangWDuYLiMZhaoGmiR-194 targets RBX1 gene to modulate proliferation and migration of gastric cancer cellsTumour Biol3623932401201510.1007/s13277-014-2849-125412959 LiZYingXChenHYePShenYPanWZhangLMicroRNA-194 inhibits the epithelial-mesenchymal transition in gastric cancer cells by targeting FoxM1Dig Dis Sci5921452152201410.1007/s10620-014-3159-624748184 ChiHmiR-194 regulated AGK and inhibited cell proliferation of oral squamous cell carcinoma by reducing PI3K-Akt-FoxO3a signalingBiomed Pharmacother715357201510.1016/j.biopha.2015.02.01125960215 ZhangMZhuangQCuiLMiR-194 inhibits cell proliferation and invasion via repression of RAP2B in bladder cancerBiomed Pharmacother80268275201610.1016/j.biopha.2016.03.02627133066 Nofech-MozesRKhellaHWScorilasAYoussefLKrylovSNLianidouESidiropoulosKGGabrilMEvansAYousefGMMicroRNA-194 is a marker for good prognosis in clear cell renal cell carcinomaCancer Med5656664201610.1002/cam4.631268600794831284 ZhangJZhaoCYZhangSHYuDHChenYLiuQHShiMNiCRZhuMHUpregulation of miR-194 contributes to tumor growth and progression in pancreatic ductal adenocarcinomaOncol Rep3111571164201424398877 KamijoTRole of stemness-related molecules in neuroblastomaPediatr Res71511515201210.1038/pr.2011.5422430387 RenHDuPGeZJinYDingDLiuXZouQTWIST1 and BMI1 in cancer metastasis and chemoresistanceJ Cancer710741080201610.7150/jca.14031273262504911874 YuanWYuanYZhangTWuSRole of Bmi-1 in regulation of ionizing irradiation-induced epithelial-mesenchymal transition and migration of breast cancer cellsPLoS One10e0118799201510.1371/journal.pone.0118799257347754348174 YangMHHsuDSWangHWWangHJLanHYYangWHHuangCHKaoSYTzengCHTaiSKBmi1 is essential in Twist1-induced epithelial-mesenchymal transitionNat Cell Biol12982992201010.1038/ncb209920818389 LeungCLingbeekMShakhovaOLiuJTangerESaremaslaniPVan LohuizenMMarinoSBmi1 is essential for cerebellar development and is overexpressed in human medulloblastomasNature428337341200410.1038/nature0238515029199 MolofskyAVPardalRIwashitaTParkIKClarkeMFMorrisonSJBmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferationNature425962967200310.1038/nature02060145743652614897 WuZWangQWangLLiGLiuHFanFLiZLiYTuYCombined aberrant expression of Bmi1 and EZH2 is predictive of poor prognosis in glioma patientsJ Neurol Sci335191196201310.1016/j.jns.2013.09.03024139839 SunPMuYZhangSA novel NF-κB/MMP-3 signal pathway involves in the aggressivity of glioma promoted by Bmi-1Tumour Biol351272112727201410.1007/s13277-014-2597-225252846 DongPKaneuchiMWatariHHamadaJSudoSJuJSakuragiNMicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1Mol Cancer1099201110.1186/1476-4598-10-99218516243173388 DengYXiongYLiuYmiR-376c inhibits cervical cancer cell proliferation and invasion by targeting BMI1Int J Exp Pathol97257265201610.1111/iep.1217727345009 WengJHYuCCLeeYCLinCWChangWWKuoYLmiR-494-3p induces cellular senescence and enhances radiosensitivity in human oral squamous carcinoma cellsInt J Mol Sci1717201610.3390/ijms17071092 HeZXiaYPanCMaTLiuBWangJChenLChenYUp-regulation of miR-452 inhibits metastasis of non-small cell lung cancer by regulating BMI1Cell Physiol Biochem37387398201510.1159/00043036226316085 ChenTXuCChenJDingCXuZLiCZhaoJMicroRNA-203 inhibits cellular proliferation and invasion by targeting Bmi1 in non-small cell lung cancerOncol Lett9263926462015261371204473497 ChengYYangXDengXZhangXLiPTaoJLuQMicroRNA-218 inhibits bladder cancer cell proliferation, migration, and invasion by targeting BMI-1Tumour Biol3680158023201510.1007/s13277-015-3532-x25967457 WangTChenTNiuHLiCXuCLiYHuangRZhaoJWuSMicroRNA-218 inhibits the proliferation and metastasis of esophageal squamous cell carcinoma cells by targeting BMI1Int J Mol Med36931022015259990244494586 XuanHXueWPanJShaJDongBHuangYDownregulation of miR-221, −30d, and −15a contributes to pathogenesis of prostate cancer by targeting Bmi-1Biochemistry (Mosc)80276283201510.1134/S000629791503003725761682 LiuLQiuMTanGLiangZQinYChenLChenHLiuJmiR-200c inhibits invasion, migration and proliferation of bladder cancer cells through down-regulation of BMI-1 and E2F3J Transl Med12305201410.1186/s12967-014-0305-z253670804226852 QiXLiJZhouCLvCTianMMicroRNA-320a inhibits cell proliferation, migration and invasion by targeting BMI-1 in nasopharyngeal carcinomaFEBS Lett58837323738201410.1016/j.febslet.2014.08.02125171860 KahlertUDNikkhahGMaciaczykJEpithelial-to-mesenchymal(−like) transition as a relevant molecular event in malignant gliomasCancer Lett331131138201310.1016/j.canlet.2012.12.01023268331 EliasMCTozerKRSilberJRMikheevaSDengMMorrisonRSManningTCSilbergeldDLGlackinCARehTATWIST is expressed in human gliomas and promotes invasionNeoplasia7824837200510.1593/neo.04352162298051501937 HanSPKimJHHanMESimHEKimKSYoonSBaekSYKimBSOhSOSNAI1 is involved in the proliferation and migration of glioblastoma cellsCell Mol Neurobiol31489496201110.1007/s10571-010-9643-421225336 MikheevaSAMikheevAMPetitABeyerROxfordRGKhorasaniLMaxwellJPGlackinCAWakimotoHGonzález-HerreroITWIST1 promotes invasion through mesenchymal change in human glioblastomaMol Cancer9194201010.1186/1476-4598-9-194206463162920263 PangHZhengYZhaoYXiuXWangJmiR-590-3p suppresses cancer cell migration, invasion and epithelial-mesenchymal transition in glioblastoma multiforme by targeting ZEB1 and ZEB2Biochem Biophys Res Commun468739745201510.1016/j.bbrc.2015.11.02526556542 LiJYuanJYuanXZhaoJZhangZWengLLiuJMicroRNA-200b inhibits the growth and metastasis of glioma cells via targeting ZEB2Int J Oncol48541550201626648487 HeXLiuZPengYYuCMicroRNA-181c inhibits glioblastoma cell invasion, migration and mesenchymal transition by targeting TGF-β pathwayBiochem Biophys Res Commun46910411048201610.1016/j.bbrc.2015.12.02126682928

The expression of miR-194 in glioma tissues and cell lines. (A) Relative miR-194 expression in glioma tissues and normal brain tissues was examined by RT-PCR. **P<0.01 vs. normal. (B) RT-qPCR analysis of miR-194 in glioma cell lines (U251, SHG44, A172 and U87) and normal human astrocytes (NHA). *P<0.05 vs. NHA.

miR-194 represses glioma cell migration and invasion. A172 and U87 cells were transiently transfected with miR-194 mimics or miR-194 inhibitors. (A) Glioma cell migration and (B) invasion were detected by Transwell assay. (C) Quantitative cell number of migrated cells. (D) Quantitative cell number of invaded cells. *P<0.05.

miR-194 inhibits glioma cell EMT. The effect of miR-194 overexpression or suppression on E-cadherin and vimentin was detected by western blot analysis in A172 (A-C) and U87 (D-F) cells. The relative expression of proteins was quantified by Image-Pro Plus 6.0 software. *P<0.05.

miR-194 targets the 3-UTR of Bmi1. (A) Schematic representation of the seed region between miR-194 and Bmi1 3-UTR. (B and C) Dual-Luciferase report assay. U87 cells were co-transfected with the miR-194 mimics or miR-194 inhibitors and report vectors containing wild-type (WT) or mutant (MT) Bmi1 3-UTR. After 48 h, the luciferase activity was analyzed by a dual-luciferase reporter assay system kit. *P<0.05.

miR-194 regulates Bmi1 expression. A172 and U87 cells were transfected with miR-194 mimics or miR-194 inhibitors for 48 h. The mRNA expression of Bmi1 in (A) A172 and (B) U87 cells was detected by RT-qPCR analysis. The protein expression of Bmi1 in (C) A172 and (D) U87 cells was detected by western blot analysis. The relative expression of proteins was quantified by Image-Pro Plus 6.0 software. *P<0.05.

miR-194 functions a tumor suppressor through Bmi1. Cells were co-transfected with miR-194 mimics and pcDNA-Bmi1 vector encoding the full-length coding sequence without the 3-UTR region. The expression levels of Bmi1, E-cadherin and vimentin in (A-D) A172 and (E-H) U87 cells were detected by western blot analysis. The relative expression of proteins was quantified by Image-Pro Plus 6.0 software. *P<0.05 vs. NC mimics; &P<0.05 vs. miR-194 mimics+vector.